Gibco Protein Expression
Thermo Fisher Scientific
Antibody-drug conjugates (ADCs) are transforming oncology by combining the precision of monoclonal antibodies with the potency of cytotoxic drugs. Yet, developing effective ADCs requires overcoming challenges at every stage—from antibody discovery and high-yield expression to conjugation chemistry and functional validation.
In this webinar, our experts Matt McKenna and Ryan Holly will present a streamlined, end-to-end ADC workflow designed to accelerate therapeutic development.
You’ll learn how Gibco™ expression platforms, GeneArt™ gene synthesis, SiteClick™ labeling technologies, and high-content imaging solutions work together to improve reproducibility, scalability, and data quality. Whether you’re advancing early discovery or optimizing downstream analysis, this session will provide practical insights to help you reduce bottlenecks, enhance consistency, and drive innovation in ADC research.
Webinar Learning Objectives:
Aspire members will receive 500 points for attending this webinar.
** Not a member? Join today to be rewarded for your commitment to science.
**This offer is available only to members of the Aspire Member Program in the US and Canada (excluding Quebec). Healthcare professionals are not eligible to participate in the Member Program. The Aspire program will award 500 bonus points for successfully attending this webinar. Determination of attendance will be at the sole discretion of Thermo Fisher Scientific. Please allow 10 business days for bonus points to credit to your account. Cannot be combined with other discounts or promotions. All terms, conditions, and restrictions of the Aspire program apply. View them here.
Webinars will be available for unlimited on-demand viewing after live event.